Company Overview

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

  • Name

    Legend Biotech Corporation

  • CEO

    Dr. Ying Huang Ph.D.

  • Website

    www.legendbiotech.com

  • Sector

    Biotechnology

  • Year Founded

    2014

Profile

  • Market Cap

    $9,372.84M

  • EV

    $8,419.93M

  • Shares Out

    183.17M

  • Revenue

    $455.99M

  • Employees

    2,200

Margins

  • Gross

    -30.76%

  • EBITDA

    -79.48%

  • Operating

    -81.89%

  • Pre-Tax

    -62.95%

  • Net

    -62.5%

  • FCF

    -35.53%

Returns (5Yr Avg)

  • ROA

    -42.93%

  • ROTA

    -207.46%

  • ROE

    -192.42%

  • ROCE

    -48.99%

  • ROIC

    -110.42%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $82.93

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $1,291.84M

  • Net Debt

    -$952.91M

  • Debt/Equity

    0.29

  • EBIT/Interest

    -16.63

Growth (CAGR)

  • Rev 3Yr

    72.46%

  • Rev 5Yr

    41.94%

  • Rev 10Yr

  • Dil EPS 3Yr

    -10.9%

  • Dil EPS 5Yr

    154%

  • Dil EPS 10Yr

  • Rev Fwd 2Yr

    88.28%

  • EBITDA Fwd 2Yr

  • EPS Fwd 2Yr

  • EPS LT Growth Est

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

NasdaqGS:LEGN